|
1
|
Mathers C, Fat DM and Boerma JT: The
Global Burden of Disease: 2004 Update. World Health Organization;
2008
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bosch FX, Ribes J, Díaz M and Cléries R:
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology. 127(Suppl 1): S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Villanueva A, Newell P, Chiang DY,
Friedman SL and Llovet JM: Genomics and signaling pathways in
hepatocellular carcinoma. Semin Liver Dis. 27:55–76. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yuen MF, Tanaka Y, Fong DY-T, Fung J, Wong
DK, Yuen JC, But DY, Chan AO, Wong BC, Mizokami M, et al:
Independent risk factors and predictive score for the development
of hepatocellular carcinoma in chronic hepatitis B. J Hepatol.
50:80–88. 2009. View Article : Google Scholar
|
|
6
|
Yang HI, Sherman M, Su J, Chen PJ, Liaw
YF, Iloeje UH and Chen CJ: Nomograms for risk of hepatocellular
carcinoma in patients with chronic hepatitis B virus infection. J
Clin Oncol. 28:2437–2444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lok AS, Seeff LB, Morgan TR, di Bisceglie
AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM,
Bonkovsky HL, et al HALT-C Trial Group: Incidence of hepatocellular
carcinoma and associated risk factors in hepatitis C-related
advanced liver disease. Gastroenterology. 136:138–148. 2009.
View Article : Google Scholar
|
|
8
|
Yeoman AD, Al-Chalabi T, Karani JB,
Quaglia A, Devlin J, Mieli-Vergani G, Bomford A, O'Grady JG,
Harrison PM and Heneghan MA: Evaluation of risk factors in the
development of hepatocellular carcinoma in autoimmune hepatitis:
Implications for follow-up and screening. Hepatology. 48:863–870.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang X, Wang N, Cheung F, Lao L, Li C and
Feng Y: Chinese medicines for prevention and treatment of human
hepatocellular carcinoma: Current progress on pharmacological
actions and mechanisms. J Integr Med. 13:142–164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lopez PM, Villanueva A and Llovet JM:
Systematic review: Evidence-based management of hepatocellular
carcinoma - an updated analysis of randomized controlled trials.
Aliment Pharmacol Ther. 23:1535–1547. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Villanueva A, Toffanin S and Llovet JM:
Linking molecular classification of hepatocellular carcinoma and
personalized medicine: Preliminary steps. Curr Opin Oncol.
20:444–453. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ke AW, Shi GM, Zhou J, Huang XY, Shi YH,
Ding ZB, Wang XY, Devbhandari RP and Fan J: CD151 amplifies
signaling by integrin α6β1 to PI3K and induces the
epithelial-mesenchymal transition in HCC Cells. Gastroenterology.
140:1629–1641.e15. 2011. View Article : Google Scholar
|
|
13
|
Kveine M, Tenstad E, Døsen G, Funderud S
and Rian E: Characterization of the novel human transmembrane
protein 9 (TMEM9) that localizes to lysosomes and late endosomes.
Biochem Biophys Res Commun. 297:912–917. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
15
|
Fang F, Yang L, Tao Y and Qin W: FBI-1
promotes cell proliferation and enhances resistance to chemotherapy
of hepatocellular carcinoma in vitro and in vivo. Cancer.
118:134–146. 2012. View Article : Google Scholar
|
|
16
|
Zhai XF, Chen Z, Li B, Shen F, Fan J, Zhou
WP, Yang YK, Xu J, Qin X, Li LQ and Ling CQ: Traditional herbal
medicine in preventing recurrence after resection of small
hepatocellular carcinoma: a multicenter randomized controlled
trial. J Integr Med. 11:90–100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morgan DO: The Cell Cycle: Principles of
Control. New Science Press. 2007.
|
|
18
|
Spilka R, Ernst C, Mehta AK and Haybaeck
J: Eukaryotic translation initiation factors in cancer development
and progression. Cancer Lett. 340:9–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okamoto H, Yasui K, Zhao C, Arii S and
Inazawa J: PTK2 and EIF3S3 genes may be amplification targets at
8q23–q24 and are associated with large hepatocellular carcinomas.
Hepatology. 38:1242–1249. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cappuzzo F, Varella-Garcia M, Rossi E,
Gajapathy S, Valente M, Drabkin H and Gemmill R: MYC and EIF3H
coamplification significantly improve response and survival of
non-small cell lung cancer patients (NSCLC) treated with gefitinib.
J Thorac Oncol. 4:472–478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jackman M, Firth M and Pines J: Human
cyclins B1 and B2 are localized to strikingly different structures:
B1 to microtubules, B2 primarily to the Golgi apparatus. EMBO J.
14:1646–1654. 1995.PubMed/NCBI
|
|
22
|
Porter LA, Singh G and Lee JM: Abundance
of cyclin B1 regulates γ-radiation-induced apoptosis. Blood.
95:2645–2650. 2000.
|
|
23
|
Rescher U and Gerke V: S100A10/p11:
Family, friends and functions. Pflugers Arch. 455:575–582. 2008.
View Article : Google Scholar
|
